Australia's most trusted
source of pharma news
Friday, 17 April 2026
Posted 17 April 2026 AM
Melbourne-based Telix Pharmaceuticals has sued Purdue Research Foundation seeking to invalidate an Australian patent protecting Novartis' radiotherapy Pluvicto to open the door to launching its competitor treatment.
Counsel for Telix told Federal Court Justice Stephen Burley in the first case management hearing this week there was some "nervousness" among clinics and services providers about using Telix's products, according to legal publication, Lawyerly.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.